Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABX464 in Moderately to Severely Active Ulcerative Colitis
NCT05507216Phase 3Completed
- Sponsor
- Abivax
- Start
- Jan 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 27
01
Overview
A Phase 3 trial of obefazimod in ulcerative colitis (UC), sponsored by Abivax. Started Jan 2023; status: completed.
02
Drugs
obefazimod
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05507216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05507216.